Prevention of Heart Failure in Type 2 Diabetes by Exercise Intervention

Type 2 Diabetes Clinical Trial

— PROTECTION  

Official title:

PROTECTION Study: PReventiOn of hearT Failure in Type 2 Diabetes by ExerCise inTerventION

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05023538
• Other study ID #: Version 1, 10/06/2021
• Status: Recruiting
• Phase: N/A
• Start date: March 1, 2022
• Est. completion date: June 1, 2026

Study information

• Verified date: March 2024
• Source: Hasselt University
• Contact: Dominique Hansen, Prof. dr.
• Phone: 0497 875866
• Email: Dominique.hansen[@]uhasselt.be
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Global longitudinal strain emerged as an important predictive marker that could be assessed during echocardiography. It enabled the detection of subclinical myocardial systolic dysfunction, without observable reductions in cardiac output or left ventricular ejection fraction, often years before diabetes induced heart failure. In asymptomatic T2D patients with no history of cardiovascular disease, an impaired global longitudinal strain is a predictor of future adverse left ventricular remodeling and adverse cardiovascular events. Exercise training is a promising intervention to interfere in the diabetes induced heart failure pathophysiology. However, the impact of different exercise modalities (e.g. intensity and volume) on the global longitudinal strain in type 2 diabetes (T2D) is unknown.

Description:

More than 400 million people worldwide are affected by diabetes mellitus whose prevalence keeps increasing. In type 2 diabetes mellitus (T2DM), up to 23% of the patients have asymptomatic diastolic and 13% systolic cardiac dysfunction. Diabetes-induced heart failure (DIHF), with reduced or preserved ejection fraction, is thus one of the major complications of T2DM, which is characterized by structural and functional changes in the myocardium in absence of coronary artery disease, other cardiac pathologies or hypertension. These changes significantly affect prognosis: patients with DIHF are at a 147% elevated risk for premature death within 4 years vs. 29% in patients without DIHF. It is thus of the utmost importance to prevent the development of DIHF. Although the exact mechanisms are not fully understood, hyperglycemia, hyperinsulinemia and hyperlipidemia are considered as key risk factors, but also oxidative and dicarbonyl stress, advanced glycation end products (AGEs) and inflammation play an important role in the pathophysiology of DIHF. To prevent adverse cardiac remodeling in T2DM and the development of DIHF, early biomarkers are mandatory. In this respect, in the past few years global longitudinal strain (GLS) emerged as an important predictive marker that could be assessed during echocardiography: the global longitudinal strain enables the detection of subclinical myocardial systolic dysfunction, without observable reductions in cardiac output or left ventricular ejection fraction, often years before DIHF. In asymptomatic T2DM patients with no history of cardiovascular disease, an impaired GLS is a predictor of future adverse left ventricular (LV) remodeling and adverse cardiovascular events, thus providing incremental prognostic value beyond clinical data, glycated hemoglobin (HbA1c) and diastolic function. The investigators found that GLS is indeed significantly lowered (by ±14%, at rest and during low-intense and high-intense exercise, in asymptomatic well-controlled T2DM patients (HbA1c: 6.9±0.7%). During exercise, GLS increases in T2DM, but fails to normalize when compared with healthy controls. In contrast to current assumption, the investigators' data demonstrate that a disturbed GLS is highly common in T2DM patients. Exercise training is strongly recommended to T2DM patients, and is a crucial treatment next to medication and diet, as this (further) optimizes glycemic control by improving insulin sensitivity, next to the positive impact on physical fitness, blood pressure, lipid profile and body composition. Recent evidence also indicates a significantly lowered mortality in habitual physically active vs. non-active T2DM patients (hazard ratio=0.61). What type of exercise is most effective? What remains debatable is whether exercise intervention can prevent the development of DIHF in asymptomatic T2DM patients. According to a recent systematic review from the investigators' laboratory, the impact of exercise intervention on GLS in asymptomatic T2DM is equivocal: significant improvements from some studies could not be reproduced in other. In line with these findings, the investigators' unpublished pilot data also reveal the capability of exercise training to improve GLS in some T2DM patients. The investigators' data show the potency of exercise in preventing DIHF in asymptomatic T2DM patients, but they also show that crucial aspects deserve further study to maximize the benefits of exercise training on GLS in T2DM patients, and hereby to offer maximal protection against the development of DIHF. The impact of different exercise modalities (e.g. intensity, volume) on GLS in T2DM patients is currently unknown. In the only clinical study that examined T2MD patients to date, results show that high-intense interval training is more effective to improve GLS, as opposed to moderate-intense exercise training. However, the study is biased due to the lack of supervision in the moderate-intense trained group and the lack of control for equal caloric expenditure between training groups. Therefore, it is likely that differences in exercise volume could be at the basis of different changes in GLS between groups. Indeed, the investigators' pilot data, in which iso-caloric interventions were compared, show different results: moderate-intense exercise training seems more potent to improve GLS, as opposed to high-intense interval training. As a result, although there is evidence that exercise training improves GLS in T2DM patients, it remains to be studied whether different volumes or intensities are of key importance. Despite following identical exercise interventions, studies and the investigators' pilot data also show significant inter-subject variances in changes in GLS. Therefore, the impact of the patient's phenotype, as well as habitual physical activity (PA) and dietary habits, on the effects of exercise training on GLS in T2DM patients is currently unknown. Revealing which (non-)modifiable patient-related factors (e.g. phenotype, habitual PA and dietary habits) predict the responsiveness of GLS to exercise intervention in T2DM patients may lead to a more patient-specific application of such intervention or further tailoring of the intervention.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 182
• Est. completion date: June 1, 2026
• Est. primary completion date: March 1, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 75 Years

Eligibility

Inclusion Criteria:

• physically inactive (no participation in structured or unstructured physical activity (PA) and not reaching the recommended PA guidelines: initially based on the International Physical Activity Questionnaire )
• age between 30-75 years
• blood HbA1c of 6-10% (if taking blood glucose lowering medication) or 6.5-10% without taking blood glucose lowering medication, and/or two-hour plasma glucose =11.1 mmol/L or =200 mg/dL following a 75g oral glucose load during OGTT.
• women of child bearing age will be included into the trial.

Exclusion Criteria:

• exogenous insulin therapy
• individuals suffering from any disease with significant impact on exercise intervention participation, such as: chronic heart disease or significant arrhythmias, cardiac events (myocardial infarction, coronary artery bypass graft, percutaneous coronary intervention), chronic obstructive pulmonary, cerebrovascular or peripheral vascular disease, severe hypertension (>160/110 mmHg), cancer, severe neuropathy (limiting exercise participation).

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Heart Failure
• Type 2 Diabetes

Intervention

Other:
• Cycling
Exercise on bicycle ergometer

Locations

Country	Name	City	State
Belgium	Faculty of Rehabilitation Sciences and Physiotherapy, Hasselt University	Hasselt
Belgium	Faculty of Movement and Rehabilitation Sciences	Leuven

Sponsors (4)

Lead Sponsor	Collaborator
Hasselt University	Jessa Hospital, KU Leuven, University Ghent

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Global longitudinal strain (%)	Cardiac function evaluation by echocardiography at rest and during maximal exercise testing	6 months
Secondary	Waist circumference (cm)	Physical examination	pre-post 6 months
Secondary	Body mass (kg)	Physical examination	pre-post 6 months
Secondary	HbA1c (mmol/mol)	Physical examination	pre-post 6 months
Secondary	Blood Glucose (mmol/L)	Physical examination	pre-post 6 months
Secondary	Insulin (mIU/L)	Physical examination	pre-post 6 months
Secondary	Blood lipid profile (total cholesterol, HDL, LDL, free fatty acids, triglycerides; mmol/L)	Physical examination	pre-post 6 months
Secondary	Peak VO2(L)	Incremental cardiopulmonary exercise test on a bicycle	pre-post 6 months
Secondary	2nd Ventilatory Treshold (%VO2peak)	Incremental cardiopulmonary exercise test on a bicycle	pre-post 6 months
Secondary	Maximal work-rate(W)	Incremental cardiopulmonary exercise test on a bicycle	pre-post 6 months
Secondary	International Physical Activity Questionnaire (MET-min/week)	Physical activity level during 7 days	pre-post 6 months
Secondary	Physical activity measurement (MET-min/week; kcal/week; steps/day; )	With ActiGraph wGT3X-BT worn on a wrist during a 1-week period. Used to obtain activity counts, energy expenditure, MET rates and steps taken.	pre-post 6 months
Secondary	Sleep quality measurement (total sleep time (h))	With ActiGraph wGT3X-BT worn on a wrist during a 1-week period.	pre-post 6 months
Secondary	Dietary intake (kcal/day)	5-day food diary	pre-post 6 months
Secondary	Calf muscle oxygen saturation (haemoglobin variables: ?HHb, ?tHb, ?HbO2 and ?TSI%)	Measured at the middle of the vastus lateralis muscle during the cardiopulomonary cycling test via non-invasive near-infrared spectroscopy (NIRS - PortaMon from ARTINIS).	pre-post 6 months